Epidemiology of chronic lymphocytic leukaemia in an Irish subpopulation with total case ascertainment: an additional tool for health economic planning

doi:10.1111/bjh.17929

Multicenter Study

. 2022 Mar;196(5):e47-e49.

doi: 10.1111/bjh.17929. Epub 2021 Nov 16.

Epidemiology of chronic lymphocytic leukaemia in an Irish subpopulation with total case ascertainment: an additional tool for health economic planning

Carmel Waldron¹, David O'Brien², Sarah Brophy³, Kanthi Perera⁴, Gerard M Crotty⁴, Eoghan Dunlea⁴, Aileen Walsh⁴, Michelle Connolly⁴, Ruth Clifford⁵, Hilary O'Leary⁵, Ashique Khan⁵, Greg Lee¹, Emer Atkinson⁶, Giao Le¹, Alexander Gillett¹, Christopher L Bacon¹, Anthony M McElligott³, Fiona Quinn⁶, Elisabeth Vandenberghe^{1

6}

Affiliations

¹ Department of Haematology, Trinity St James's Cancer Institute, Dublin, Ireland.
² Flow Cytometry Laboratory, Trinity St James's Cancer Institute, Dublin, Ireland.
³ John Durkan Leukaemia Laboratories, Institute of Molecular Medicine, Trinity St. James's Cancer Institute, Dublin, Ireland.
⁴ Department of Haematology, Midlands Regional Hospital, Tullamore, Ireland.
⁵ Department of Haematology, University Hospital Limerick, Limerick, Ireland.
⁶ Cancer Molecular Diagnostics Laboratory, Trinity St James's Cancer Institute, Dublin, Ireland.

PMID: 34783371
DOI: 10.1111/bjh.17929

Multicenter Study

Epidemiology of chronic lymphocytic leukaemia in an Irish subpopulation with total case ascertainment: an additional tool for health economic planning

Carmel Waldron et al. Br J Haematol. 2022 Mar.

. 2022 Mar;196(5):e47-e49.

doi: 10.1111/bjh.17929. Epub 2021 Nov 16.

Authors

Affiliations

¹ Department of Haematology, Trinity St James's Cancer Institute, Dublin, Ireland.
² Flow Cytometry Laboratory, Trinity St James's Cancer Institute, Dublin, Ireland.
³ John Durkan Leukaemia Laboratories, Institute of Molecular Medicine, Trinity St. James's Cancer Institute, Dublin, Ireland.
⁴ Department of Haematology, Midlands Regional Hospital, Tullamore, Ireland.
⁵ Department of Haematology, University Hospital Limerick, Limerick, Ireland.
⁶ Cancer Molecular Diagnostics Laboratory, Trinity St James's Cancer Institute, Dublin, Ireland.

PMID: 34783371
DOI: 10.1111/bjh.17929

No abstract available

Keywords: TP53; chronic lymphocytic leukaemia; epidemiology; incidence; targeted therapies.

PubMed Disclaimer

Cited by

Synthesis and Biochemical Evaluation of Ethanoanthracenes and Related Compounds: Antiproliferative and Pro-Apoptotic Effects in Chronic Lymphocytic Leukemia (CLL).
McKeown JP, Byrne AJ, Bright SA, Charleton CE, Kandwal S, Čmelo I, Twamley B, McElligott AM, Fayne D, O'Boyle NM, Williams DC, Meegan MJ. McKeown JP, et al. Pharmaceuticals (Basel). 2024 Aug 5;17(8):1034. doi: 10.3390/ph17081034. Pharmaceuticals (Basel). 2024. PMID: 39204139 Free PMC article.
Low CD49d expression in newly diagnosed chronic lymphocytic leukaemia may be associated with high-risk features and reduced treatment-free-intervals.
Elizabeth S, Aidan K, David OB, Deirdre W, Sarah B, Emer A, Kanthi P, Crotty GM, Aileen W, Michelle C, Ruth C, Hilary O, Ashique K, Bacon CL, Emily S, McElligott AM, Fiona Q, Elisabeth V, Carmel W. Elizabeth S, et al. Eur J Haematol. 2022 Nov;109(5):441-446. doi: 10.1111/ejh.13824. Epub 2022 Aug 9. Eur J Haematol. 2022. PMID: 35776688 Free PMC article.

References

1. SEER*explorer: an interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. 2021. Available from: http://seer.cancer.gov/explorer/
1. National Cancer Registry Ireland. Cancer in Ireland 1994-2018 with estimates for 2018-2020: annual report of the National Cancer Registry. NCRI, Cork, Ireland. [Internet]. 2020. Available from: https://ncri.ie/data
1. Scarfo L, Ferreri AJ, Ghia P. Chronic lymphocytic leukaemia. Crit Rev Oncol Hematol. 2016;104:169-82.
1. Dreger P, Ghia P, Schetelig J, van Gelder M, Kimby E, Michallet M, et al. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood. 2018;132:892-902.
1. Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:481-8.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

[1] SEER*explorer: an interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. 2021. Available from: http://seer.cancer.gov/explorer/

[2] SEER*explorer: an interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. 2021. Available from: http://seer.cancer.gov/explorer/

[3] National Cancer Registry Ireland. Cancer in Ireland 1994-2018 with estimates for 2018-2020: annual report of the National Cancer Registry. NCRI, Cork, Ireland. [Internet]. 2020. Available from: https://ncri.ie/data

[4] National Cancer Registry Ireland. Cancer in Ireland 1994-2018 with estimates for 2018-2020: annual report of the National Cancer Registry. NCRI, Cork, Ireland. [Internet]. 2020. Available from: https://ncri.ie/data

[5] Scarfo L, Ferreri AJ, Ghia P. Chronic lymphocytic leukaemia. Crit Rev Oncol Hematol. 2016;104:169-82.

[6] Scarfo L, Ferreri AJ, Ghia P. Chronic lymphocytic leukaemia. Crit Rev Oncol Hematol. 2016;104:169-82.

[7] Dreger P, Ghia P, Schetelig J, van Gelder M, Kimby E, Michallet M, et al. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood. 2018;132:892-902.

[8] Dreger P, Ghia P, Schetelig J, van Gelder M, Kimby E, Michallet M, et al. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood. 2018;132:892-902.

[9] Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:481-8.

[10] Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:481-8.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Epidemiology of chronic lymphocytic leukaemia in an Irish subpopulation with total case ascertainment: an additional tool for health economic planning

Affiliations

Epidemiology of chronic lymphocytic leukaemia in an Irish subpopulation with total case ascertainment: an additional tool for health economic planning

Authors

Affiliations

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous